FDU-PB-22 is a chemical compound believed to be a highly active stimulant of the CB1 receptor, derived from JWH-018, and has been distributed over the internet as a synthetic designer drug.
|Chemical and physical data|
|Molar mass||395.433 g·mol−1|
FDU-PB-22 functions as a complete agonist, exhibiting a binding affinity of 1.19nM at CB1 and 2.43nM at CB2 cannabinoid receptors.
In terms of its legal status, FDU-PB-22 is classified as a controlled substance in Germany and is prohibited in Japan and Sweden.
- What is FDU-PB-22?
- FDU-PB-22 is a synthetic cannabinoid that acts as a potent agonist on the CB1 and CB2 cannabinoid receptors. It is commonly associated with designer drugs and recreational use.
- How does FDU-PB-22 work?
- FDU-PB-22 interacts with the CB1 and CB2 receptors in the endocannabinoid system, producing various physiological and psychoactive effects when consumed.
- What are the effects of FDU-PB-22 use?
- Effects of FDU-PB-22 use may include altered perception, relaxation, and increased heart rate, among others. However, it can also lead to adverse effects like anxiety and paranoia.
- Is FDU-PB-22 legal?
- The legal status of FDU-PB-22 varies by country. It is classified as a controlled substance in some regions, while it is banned in others, such as Japan and Sweden. It’s crucial to be aware of the legal status in your area.
- What are the risks associated with FDU-PB-22 use?
- FDU-PB-22 and similar synthetic cannabinoids have been associated with various health risks, including addiction potential, cardiovascular issues, and psychological side effects. Long-term effects are not well understood due to limited research.
- Is FDU-PB-22 safe to use?
- Using FDU-PB-22 is not considered safe due to the lack of research on its long-term effects and potential health risks. It is advised to avoid its use.
- How can I get help for FDU-PB-22 addiction or adverse effects?
- If you or someone you know is struggling with FDU-PB-22 addiction or experiencing adverse effects, seek medical help and support from addiction specialists and healthcare professionals.
- Is FDU-PB-22 commonly found in recreational products?
- FDU-PB-22 has been reported in designer drugs and synthetic cannabinoid products, particularly those marketed as alternatives to traditional cannabis. However, its presence in such products can vary.
- Can FDU-PB-22 be detected in drug tests?
- FDU-PB-22 and similar synthetic cannabinoids may or may not be detected in standard drug tests. Specific tests are required to see these substances, and their inclusion in routine drug screenings may vary.
- What should I do if I encounter FDU-PB-22 or similar substances?
- If you come across FDU-PB-22 or related synthetic cannabinoids, it’s advisable to avoid them and report any suspicious substances to the relevant authorities to protect public health and safety.
- “FDU-PB-22”. The Southern Association of Forensic Scientists. The information is archived, dating back to May 27, 2015, and was retrieved on July 23, 2015.
- Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T (July 1, 2015). “N-OH-EDMA, and a novel cathinone derivative known as dimethoxy-α-PHP, have been recently identified in illicit substances.” This research was published in Forensic Toxicology, Volume 33, Issue 2, spanning pages 244 to 259. doi:10.1007/s11419-015-0268-7. The article is available via PMC (PubMed Central) under the reference PMC 4525202, and the PMID (PubMed ID) is 26257833.
- Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (July 1, 2016). “An in-depth pharmacological assessment of synthetic cannabinoids, which have been identified as components of spice mixtures.” This study is featured in Forensic Toxicology, Volume 34, Issue 2, with pages ranging from 329 to 343. doi:10.1007/s11419-016-0320-2. The article is accessible via PMC (PubMed Central) under the reference PMC 4929166, and the PMID (PubMed ID) is 27429655.
- “Cannabinoider föreslås bli klassificerade som hälsofarlig vara” (translation: “Cannabinoids proposed to be classified as a health-hazardous product”). Published by Folkhälsomyndigheten on May 28, 2014. The information was retrieved on July 23, 2015.